Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G for Aclaris Therapeutics Inc Common Stock (ACRS).
- Disclosed ownership: 6.2%.
- Date of event: 30 Jun 2025.
VANGUARD GROUP INC - 30 Jun 2025 SCHEDULE 13G Report for Aclaris Therapeutics Inc Common Stock (ACRS)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Symbol
- ACRS
- Shares outstanding
- 108,326,228 shares
- Disclosed Ownership
- 6,662,063 shares
- Ownership
- 6.2%
- Form type
- SCHEDULE 13G
- Filing time
- 29 Jul 2025, 11:22:32 UTC
- Date of event
- 30 Jun 2025
- Previous filing
- 30 Apr 2025
- Next filing
- 26 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 6.2% ownership in Aclaris Therapeutics Inc Common Stock (ACRS) on 30 Jun 2025."
What Changed
- Previous schedule filing date: 30 Apr 2025.
- Current filing was accepted on 29 Jul 2025, 11:22.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 6.2% | 6,662,063 | 0 | 37,768 | Ashley Grim | Head of Global Fund Administration |